U.S. Pharmaceutical Market To Witness Massive Growth By 2030

U.S. Pharmaceutical Market Summary

The U.S. pharmaceutical market size was estimated at USD 634.32 billion in 2024 and is expected to expand at a CAGR of 5.72% from 2025 to 2030, reaching an estimated value of USD 883.97 billion by 2030. This steady growth is largely driven by the increasing prevalence of chronic diseases such as diabetes, cardiovascular disorders, and cancer, along with a rapidly aging population that requires long-term medical care. Additionally, the rising healthcare expenditure by government organizations, continuous investments in research and development, and policy initiatives aimed at improving affordability and accessibility of drugs are collectively strengthening the market landscape.

The U.S. pharmaceutical industry has seen remarkable expansion, supported by scientific innovation and a robust product pipeline. Breakthroughs in targeted therapies, biologics, and personalized medicine have transformed the treatment paradigm, offering tailored and more effective options for managing complex medical conditions. Gene therapies and RNA-based medicines, including those developed for rare genetic disorders and advanced cancers, have gained FDA approvals and are reshaping future treatment models. A major milestone has been the approval of CAR-T cell therapies, which represent a new era of precision medicine, addressing previously untreatable conditions. The progress in immuno-oncology continues to redefine cancer care by harnessing the immune system to deliver long-term and durable treatment responses.

Key Market Trends & Insights

• Based on molecule type, conventional drugs (small molecules) dominated the U.S. market with a revenue share of 54.7% in 2024. Their dominance can be attributed to strong manufacturing infrastructure, predictable pharmacokinetics, and favorable oral bioavailability, which ensure effective drug delivery and wide patient adoption.
• The branded segment held the largest share, accounting for 66.86% of revenue in 2024. This leadership is supported by the growing prevalence of chronic diseases, increased investments in R&D, and the launch of innovative therapies across multiple therapeutic areas. The introduction of new branded drugs has significantly contributed to addressing unmet needs and improving patient quality of life.
• The prescription drug segment captured the largest revenue share of 86.76% in 2024. Its growth is fueled by ongoing advancements in drug discovery, particularly in biologics and precision-based treatments, which have enhanced outcomes in challenging therapeutic areas. Prescription medicines remain crucial for managing both acute and chronic diseases, ensuring consistent growth in this segment.
• The cancer segment emerged as the leading therapeutic area, contributing a revenue share of 17.07% in 2024. The rising incidence of various cancers has created an urgent demand for more effective treatment options, resulting in significant investments in oncology research. Continuous innovation, clinical trials, and targeted cancer therapies have made oncology a dominant driver of the pharmaceutical market.
• By route of administration, oral drugs accounted for the largest share of 57.5% in 2024. Oral delivery continues to be the most preferred option due to its ease of use, non-invasiveness, and patient-friendly attributes, making it a cornerstone of drug consumption.
• The adults segment represented the largest market share at 62.84% in 2024 and is expected to record the fastest CAGR during the forecast period. Adults, particularly those aged 15–64 years, make up the largest proportion of the population and are the primary consumers of prescription medicines for both acute and chronic conditions, ensuring steady demand growth.
• The hospital pharmacy segment dominated the market with a 53.53% revenue share in 2024. Hospital pharmacies play a critical role in the pharmaceutical distribution ecosystem by ensuring timely availability of essential medicines, supporting inpatient treatment, and facilitating access to specialized therapies that often require professional administration and monitoring.

Order a free sample PDF of the U.S. Pharmaceutical Market Intelligence Study, published by Grand View Research.

Market Size & Forecast

• 2024 Market Size: USD 634.32 billion
• 2030 Projected Market Size: USD 883.97 billion
• CAGR (2025 - 2030): 5.72%

Key Companies & Market Share Insights

The leading companies in the pharmaceutical and drug development industries are always focusing on developing and upgrading existing technologies that serve to enhance patient outcomes and significantly increase healthcare effectiveness and efficiency. For Instance, in May 2023, Pfizer Inc. received FDA approval for PAXLOVID (nirmatrelvir tablets and ritonavir tablets) used for the treatment of patient with mild-to-moderate COVID-19. Moreover, the company also announced plans to launch 10 new formulations in the market including two oncology and immuno-inflammation medication each, and five vaccines in 2023.

Key Players

• F. Hoffmann-La Roche Ltd
• Novartis AG
• AbbVie Inc.
• Johnson & Johnson Services, Inc.
• Merck & Co., Inc.
• Pfizer Inc.
• Bristol-Myers Squibb Company
• Sanofi
• GSK plc.
• Takeda Pharmaceutical Company Limited

Explore Horizon Databook – The world's most expansive market intelligence platform developed by Grand View Research.

Conclusion

The U.S. pharmaceutical market is positioned for sustained expansion, driven by demographic shifts, rising chronic disease burden, and continuous advancements in drug discovery and development. With conventional drugs, branded therapies, and prescription medicines dominating the landscape, the industry continues to meet diverse healthcare needs. The growing focus on oncology, precision medicine, and biologics underscores the sector’s commitment to innovation and improved patient outcomes. Segments such as oral administration and hospital pharmacies further strengthen market accessibility. As government and private initiatives enhance affordability and access, the pharmaceutical industry will remain a cornerstone of U.S. healthcare, fostering progress and long-term growth.